Egg-based influenza vaccines are deemed safe for all persons aged 6 months and older with egg allergy without additional safety measures, according to results presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 Annual Meeting, held from February 23 to 26 in Washington, DC.
Investigators from the Centers for Disease Control (CDC) and Vanderbilt University analyzed reports from 31 studies that included individuals with egg allergy after receipt of full-dose (one-step) and split-dose (two-step) influenza vaccination.
Critical outcomes, defined as death, anaphylaxis and hospitalizations following vaccine administration, were collected. Additionally, important outcomes, defined as reactions requiring outpatient medical attention and reactions involving cardiovascular or respiratory symptoms, angioedema, or generalized urticaria following vaccine administration, were obtained.
Findings showed there were no instances of critical outcomes after administration of egg-based influenza vaccines. Important outcomes were reported at less than 1.5% and were deemed to be less serious reactions. Brighton Level 1 anaphylaxis associated with monovalent vaccine was reported in 1 patient in vaccine surveillance data.
Study authors concluded that the administration of egg-based influenza vaccines “is safe for all persons aged 6 months or older with egg allergy” and that “no additional safety measures are needed beyond those recommended for recipients of any vaccine.”
This article originally appeared on MPR.
References:
Blanton L, Hummell D, Moro P, et al. Safety of influenza vaccines in persons with egg allergy a systematic review. Presented at: American Academy of Allergy, Asthma & Immunology Annual Meeting; February 23 to 26, 2024; Washington, DC. Poster #185.
